Home › Funds › Tri Locum Partners LP › ASND

Tri Locum Partners LP position in ASND

ASCENDIS PHARMA A/S · Health Care

Tri Locum Partners LP reported holding 258,740 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$69.0M, representing 8.49% of its reported portfolio and ranking #4 among its reported holdings. Tri Locum Partners LP has disclosed ASND holdings in 9 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)258.74K sh
Reported value held$69.01M
Portfolio Weight8.49%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tri Locum Partners LP's ASND position evolved

Tri Locum Partners LP first disclosed a stake in ASND in Q4 2023 at 99,550 shares (US$12.5M). The position peaked in Q2 2026 at 258,740 shares, worth US$69.0M. Across 9 filings, Tri Locum Partners LP increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 258,740 shares valued at US$69.0M — an increase of 3,408 shares quarter over quarter.. Notable position changes include a 102% increase in Q2 2024 (shares rose 9% over the following quarter), a 357% increase in Q2 2025 (shares rose 15% over the following quarter), a 52% increase in Q4 2025 (shares rose 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 99.55K $12.54M New
Q1 2024 112.67K $17.03M Add
Q2 2024 227.76K $31.06M Add
Q1 2025 32.33K $5.04M New
Q2 2025 147.64K $25.48M Add
Q3 2025 174.83K $34.76M Add
Q4 2025 265.01K $56.51M Add
Q1 2026 255.33K $58.40M Reduce
Q2 2026 258.74K $69.01M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has Tri Locum Partners LP held ASND?

Tri Locum Partners LP has disclosed ASND holdings in 9 of the last 11 reported quarters, going back to Q4 2023.

What is Tri Locum Partners LP's current position in ASND?

As of Q2 2026, Tri Locum Partners LP holds 258.74K shares of ASND (ASCENDIS PHARMA A/S), valued at $69.01M, representing 8.49% of its reported portfolio and ranking #4.

Has Tri Locum Partners LP been buying or selling ASND?

In the latest 13F filing (Q2 2026), Tri Locum Partners LP increased its position in ASND. The position peaked in Q2 2026 at 258.74K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.